ATE253364T1 - Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen - Google Patents

Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen

Info

Publication number
ATE253364T1
ATE253364T1 AT99961750T AT99961750T ATE253364T1 AT E253364 T1 ATE253364 T1 AT E253364T1 AT 99961750 T AT99961750 T AT 99961750T AT 99961750 T AT99961750 T AT 99961750T AT E253364 T1 ATE253364 T1 AT E253364T1
Authority
AT
Austria
Prior art keywords
olanzapine
disorder
oxide
treatment
oxides
Prior art date
Application number
AT99961750T
Other languages
English (en)
Inventor
William E Yelle
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ATE253364T1 publication Critical patent/ATE253364T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99961750T 1998-11-23 1999-11-22 Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen ATE253364T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10955198P 1998-11-23 1998-11-23
PCT/US1999/027644 WO2000030649A1 (en) 1998-11-23 1999-11-22 Pharmaceutical compositions containing olanzapine-n-oxide

Publications (1)

Publication Number Publication Date
ATE253364T1 true ATE253364T1 (de) 2003-11-15

Family

ID=22328264

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99961750T ATE253364T1 (de) 1998-11-23 1999-11-22 Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen

Country Status (9)

Country Link
US (3) US6121259A (de)
EP (1) EP1135136B1 (de)
JP (1) JP2002530340A (de)
AT (1) ATE253364T1 (de)
AU (1) AU757870B2 (de)
CA (1) CA2351719A1 (de)
DE (1) DE69912635T2 (de)
ES (1) ES2211205T3 (de)
WO (1) WO2000030649A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2364211A1 (en) * 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
US7973043B2 (en) * 2002-07-30 2011-07-05 Peter Migaly Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
NZ540054A (en) 2002-12-27 2007-09-28 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
WO2007137224A2 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Method of treatment
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
CN101711236B (zh) * 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
WO2013152105A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US5627178A (en) * 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CA2232559A1 (en) * 1995-09-29 1997-04-03 Charles Merritt Beasley Jr. Method for treating a tic disorder
AU1335397A (en) * 1995-12-21 1997-07-17 Eli Lilly And Company Method for treating dermatitis
AU705834B2 (en) * 1995-12-22 1999-06-03 Eli Lilly And Company Method for treating depression
CN1213966A (zh) * 1996-03-11 1999-04-14 伊莱利利公司 治疗两极紊乱的方法
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
DE69733321D1 (de) * 1996-03-11 2005-06-23 Lilly Co Eli Olanzapine zur behandlung von drogenmissbrauch
BR9612552A (pt) * 1996-03-11 1999-07-20 Lilly Co Eli Processo para tratamento de autismo
GB9615767D0 (en) * 1996-07-26 1996-09-04 Smithkline Beecham Plc Novel treatment

Also Published As

Publication number Publication date
EP1135136A1 (de) 2001-09-26
AU757870B2 (en) 2003-03-06
DE69912635T2 (de) 2004-05-13
JP2002530340A (ja) 2002-09-17
ES2211205T3 (es) 2004-07-01
EP1135136B1 (de) 2003-11-05
US6121259A (en) 2000-09-19
AU1826600A (en) 2000-06-13
DE69912635D1 (de) 2003-12-11
WO2000030649A1 (en) 2000-06-02
US20020065272A1 (en) 2002-05-30
US6352984B1 (en) 2002-03-05
CA2351719A1 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
DE69912635D1 (de) Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
ATE286398T1 (de) Desmethylolanzapine enthaltende zusammensetzungen und verfahren
BRPI0413022A (pt) derivados de 3-amino cromado e 2-amino tetralina
FI963294A (fi) Naftyyliamidit keskushermostoaineina
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
BRPI0402420A (pt) Processos de toner
BRPI0416566A (pt) tratamento de fenilcetonúrias com bh4
DK1253918T3 (da) Præparater der omfatter modafinil til behandling af forstyrrelse af opmærksomhed og aktivitet ("Attention Deficit Hyperactivity Disorder" ADHD))
DE69917957D1 (de) Blockcopolymerzusammensetzung für die Modifikation von Asphalt, und Asphaltzusammensetzung enthaltend diese Blockcopolymerzusammensetzung
Quoniam et al. Implicit and explicit emotional memory for melodies in Alzheimer's disease and depression
ATE233318T1 (de) Spezifische oligonukleotide für hepatitis b virus
DE60231507D1 (de) Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
PT1047449E (pt) Composicoes imunologicas e metodos de utilizacao para alterar transitoriamente a mielina do sistema nervoso central mamifero para promover a regeneracao neuronal
BRPI0400038A (pt) Reciclo de condensados excedentes do resfriamento em um processo para purificação de acrilonitrila
DE69808119D1 (de) Diskontinuierliches und kontinuierliches gegenstromstoffaustauschverfahren
Brüne The incidence of akathisia in bipolar affective disorder treated with neuroleptics—a preliminary report
Lee et al. Effects of School Safety Education on Safety Behavior among Elementary School Students.
JP2000319390A5 (de)
Laurent The scent of music
BR0305381A (pt) Composição cosmética, usos de uma composição e processo de lavagem e condicionamento dos cabelos
유정 Narrative Intervention for Older Adults
Hirai et al. Correction to: Comparison of the social responsiveness scale-2 among individuals with Autism Spectrum Disorder and Williams Syndrome in Japan
Fountoulakis et al. Treatment of bipolar disorder: a systematic review of available data
Sussman Helping us to help you better.
Beard Bipolar disorders: Clinical course and outcome

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties